Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clervonafusp alfa - Valerion Therapeutics

Next Previous
Drug Profile

Clervonafusp alfa - Valerion Therapeutics

Alternative Names: VAL-1221

Latest Information Update: 11 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Valerion Therapeutics
  • Developer Parasail; Valerion Therapeutics
  • Class Recombinant fusion proteins
  • Mechanism of Action Alpha-glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lafora disease
  • Phase I/II Glycogen storage disease type II

Most Recent Events

  • 05 Jul 2023 Clinical trials in Lafora disease (In adolescents, In adults) (IV) (NCT05930223)
  • 19 Apr 2023 Phase-II clinical trials in Lafora disease (In adolescents, In adults) in Italy (IV) (EudraCT2023-000185-34)
  • 02 Jun 2020 Valerion Therapeutics terminates a phase I/II trial in Glycogen storage disease type II in USA and United Kingdom, due to lack of funding (NCT02898753) (EudraCT2016-004578-16)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top